文献速递炎症性肠病

维得利珠单抗与炎症性肠病患者固有免疫而非适应性免疫的变化相关

Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
PubMed 文献 · Gut · 2018-05-05

该研究对炎症性肠病患者使用维得利珠单抗(n=18)或以英夫利西单抗为对照(n=20)治疗前后进行免疫表型分析、免疫组化、T细胞受体谱分析和RNA测序,并采用单光子发射计算机断层扫描和共聚焦内镜评估体内白细胞转运。结果显示维得利珠单抗未改变固有层T细胞丰度或表型,也未影响黏膜T细胞受体库或体内白细胞转运,但显著影响固有免疫包括巨噬细胞群变化及微生物感知、趋化吸引和固有效应应答调节相关分子表达的改变。

要点

  • 维得利珠单抗未改变固有层T细胞丰度、表型、黏膜T细胞受体库或体内白细胞转运。
  • 维得利珠单抗对固有免疫有显著影响,包括巨噬细胞群变化及微生物感知、趋化吸引相关分子表达改变。
  • 上述固有免疫效应为维得利珠单抗特有,英夫利西单抗未观察到,且与肠道炎症抑制相关。

核心结论

  • 研究提示维得利珠单抗对固有免疫的调节有助于其在炎症性肠病中的治疗疗效。

研究设计与样本

  • 研究纳入炎症性肠病患者,维得利珠单抗组 n=18,英夫利西单抗对照组 n=20。
  • 在治疗前和治疗期间采集血液和结肠活检,进行免疫表型分析、免疫组化、T细胞受体谱分析和RNA测序。
  • 采用单光子发射计算机断层扫描和共聚焦内镜评估体内白细胞转运。

主要发现

  • 维得利珠单抗未伴随固有层T细胞丰度或表型的改变,未影响黏膜T细胞受体库或体内白细胞转运。
  • α4β7抗体治疗对固有免疫有实质性影响,包括巨噬细胞群变化及微生物感知、趋化吸引和固有效应应答调节相关分子表达的显著改变。
  • 上述效应为维得利珠单抗特有,英夫利西单抗未观察到,且与肠道炎症抑制相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Vedolizumab, a monoclonal antibody directed against the integrin heterodimer α4β7, is approved for the treatment of Crohn's disease and ulcerative colitis. The efficacy of vedolizumab has been suggested to result from inhibition of intestinal T cell trafficking although human data to support this conclusion are scarce. We therefore performed a comprehensive analysis of vedolizumab-induced alterations in mucosal and systemic immunity in patients with inflammatory bowel disease (IBD), using anti-inflammatory therapy with the TNFα antibody infliximab as control. DESIGN: Immunophenotyping, immunohistochemistry, T cell receptor profiling and RNA sequencing were performed using blood and colonic biopsies from patients with IBD before and during treatment with vedolizumab (n=18) or, as control, the anti-TNFα antibody infliximab (n=20). Leucocyte trafficking in vivo was assessed using single photon emission computed tomography and endomicroscopy. RESULTS: Vedolizumab was not associated with alterations in the abundance or phenotype of lamina propria T cells and did not affect the mucosal T cell repertoire or leucocyte trafficking in vivo. Surprisingly, however, α4β7 antibody treatment was associated with substantial effects on innate immunity including changes in macrophage populations and pronounced alterations in the expression of molecules involved in microbial sensing, chemoattraction and regulation of the innate effector response. These effects were specific to vedolizumab, not observed in response to the TNFα antibody infliximab, and associated with inhibition of intestinal inflammation. CONCLUSION: Our findings suggest that modulation of innate immunity contributes to the therapeutic efficacy of vedolizumab in IBD. TRIAL REGISTRATION NUMBER: NCT02694588.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Zeissig S, Rosati E, Dowds CM, et al. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease. Gut. 2018. PMID: 29730603. doi:10.1136/gutjnl-2018-316023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。